Ceska Gynekologie · 2026

Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?

By Fait T, Šimková S, Dvořáková V

Oral menopause hormone therapy (MHT) is associated with a two- to four-fold increased risk of venous thromboembolism (VTE). According to the majority of studies, the increased risk of venous thromboembolic disease does not apply to transdermal administration. Transdermal MHT is considered safe even in women at a high risk of thromboembolic disease (such as those with overweight, obesity, thrombophilic conditions, recent surgery, immobilization, varicose veins, malignancy, or smoking). Acute VTE represents an absolute contraindication to both oral and transdermal administration of MHT. A personal history of VTE is an absolute contraindication to oral MHT, but only a relative contraindication for the transdermal route of MHT. Menopause hormone therapy must be personalized for each woman.

doi.org/10.48095/cccg2026408PubMed 42988595Interventions

AgingResearch.News